{'fraction_non_alphanumeric': 0.018832391713747645, 'fraction_numerical': 0.0, 'mean_word_length': 5.734177215189874, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight‐based dose using a front‐loading schedule in patients with anemia who have nonmyeloid malignancies

The effect of using fixed versus weight‐based doses for erythropoietic agents has not been reported previously. To investigate this issue, the authors conducted a randomized Phase II study of darbepoetin alfa administered as either a fixed dose or a weight‐based dose using an accelerated correction and maintenance dosing regimen (front‐loading).